Literature DB >> 21748517

Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer.

Takaaki Arigami1, Yoshikazu Uenosono, Sumiya Ishigami, Takahiko Hagihara, Naoto Haraguchi, Shoji Natsugoe.   

Abstract

BACKGROUND: The B7-H4 coregulatory molecule is a member of the B7 family of molecules, which regulate the T-cell-mediated immune response through CD28 receptors. Recently, B7-H4 has been reported to be a negative regulator of the immune response in patients with several malignant diseases. However, few reports have investigated the clinical significance of B7-H4 expression in patients with gastric cancer. In the present study, we analyzed B7-H4 expression and the relationship between its expression and clinicopathological factors including prognosis in gastric cancer.
METHODS: B7-H4 expression in gastric cancer cell lines and clinical gastric cancer specimens was initially assessed with the reverse transcription-polymerase chain reaction (RT-PCR). Moreover, B7-H4 and CD3 expression in 120 resected specimens from gastric cancer patients were evaluated by immunohistochemistry (IHC).
RESULTS: B7-H4 expression was identified in the gastric cancer cell lines and clinical tumor tissues by RT-PCR. B7-H4 expression was high in 25.8% (31/120) of resected tumor specimens. B7-H4 expression significantly correlated with tumor stage (P = 0.04). The 5-year survival rate was significantly lower in patients with high B7-H4 expression than in those with low B7-H4 expression (P = 0.001). Multivariate analysis demonstrated that B7-H4 expression was an independent prognostic factor (P = 0.035). Immunohistochemical analysis of CD3 expression showed that B7-H4 expression was inversely correlated with the number of tumor infiltrating T lymphocytes (P < 0.001).
CONCLUSIONS: The B7-H4 coregulatory molecule is a novel prognostic marker related to the T-cell-mediated immune response, and its pathway may be a molecular target for controlling tumor progression in patients with gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21748517     DOI: 10.1007/s00268-011-1186-4

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  28 in total

1.  Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer.

Authors:  Jingting Jiang; Yibei Zhu; Changping Wu; Yueping Shen; Wenxiang Wei; Lujun Chen; Xiao Zheng; Jing Sun; Binfeng Lu; Xueguang Zhang
Journal:  Cancer Immunol Immunother       Date:  2010-08-20       Impact factor: 6.968

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

3.  Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma.

Authors:  Jing Sun; Lu-jun Chen; Guang-bo Zhang; Jing-ting Jiang; Ming Zhu; Yan Tan; Hai-tao Wang; Bin-feng Lu; Xue-guang Zhang
Journal:  Cancer Immunol Immunother       Date:  2010-03-24       Impact factor: 6.968

4.  B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.

Authors:  Iris Simon; Shaoqiu Zhuo; Laura Corral; Eleftherios P Diamandis; Mark J Sarno; Robert L Wolfert; Nam W Kim
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

5.  The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation.

Authors:  Susana Salceda; Tenny Tang; Muriel Kmet; Andrei Munteanu; Malavika Ghosh; Roberto Macina; Wenhui Liu; Glenn Pilkington; Jackie Papkoff
Journal:  Exp Cell Res       Date:  2005-05-15       Impact factor: 3.905

Review 6.  The B7 family and cancer therapy: costimulation and coinhibition.

Authors:  Xingxing Zang; James P Allison
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

7.  Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.

Authors:  Ilona Kryczek; Shuang Wei; Gefeng Zhu; Leann Myers; Peter Mottram; Pui Cheng; Lieping Chen; George Coukos; Weiping Zou
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

8.  B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.

Authors:  Iris Simon; Dionyssios Katsaros; Irene Rigault de la Longrais; Marco Massobrio; Andreas Scorilas; Nam W Kim; Mark J Sarno; Robert L Wolfert; Eleftherios P Diamandis
Journal:  Gynecol Oncol       Date:  2007-05-11       Impact factor: 5.482

9.  Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct.

Authors:  Nida S Awadallah; Kenneth R Shroyer; Daniel A Langer; Kathleen C Torkko; Yang K Chen; Joel S Bentz; Jackie Papkoff; Wenhui Liu; S Russell Nash; Raj J Shah
Journal:  Pancreas       Date:  2008-03       Impact factor: 3.327

10.  Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer.

Authors:  T Arigami; S Natsugoe; Y Uenosono; H Arima; Y Mataki; K Ehi; S Yanagida; S Ishigami; S Hokita; T Aikou
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

View more
  26 in total

1.  B7-H4 downregulation induces mitochondrial dysfunction and enhances doxorubicin sensitivity via the cAMP/CREB/PGC1-α signaling pathway in HeLa cells.

Authors:  Hyoung Kyu Kim; In-Sung Song; Sun Young Lee; Seung Hun Jeong; Sung Ryul Lee; Hye Jin Heo; Vu Thi Thu; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Dae Hun Jeong; Young Nam Kim; Jin Han
Journal:  Pflugers Arch       Date:  2014-12       Impact factor: 3.657

2.  Host b7x promotes pulmonary metastasis of breast cancer.

Authors:  Yael M Abadi; Hyungjun Jeon; Kim C Ohaegbulam; Lisa Scandiuzzi; Kaya Ghosh; Kimberly A Hofmeyer; Jun Sik Lee; Anjana Ray; Claudia Gravekamp; Xingxing Zang
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

Review 3.  Potential targeting of B7-H4 for the treatment of cancer.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

4.  Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis.

Authors:  Ninu Maskey; Kai Li; Min Hu; Zhigao Xu; Chunwei Peng; Fang Yu; Hong Cao; Jiamei Chen; Yan Li; Guifang Yang
Journal:  Tumour Biol       Date:  2014-09-27

Review 5.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

Review 6.  New B7 Family Checkpoints in Human Cancers.

Authors:  Ling Ni; Chen Dong
Journal:  Mol Cancer Ther       Date:  2017-07       Impact factor: 6.261

7.  B7-H6 protein expression has no prognostic significance in human gastric carcinoma.

Authors:  Xiao-Juan Chen; Jin Shen; Guang-Bo Zhang; Wei-Chang Chen
Journal:  Pathol Oncol Res       Date:  2013-11-16       Impact factor: 3.201

8.  B7-H4 overexpression correlates with a poor prognosis for cervical cancer patients.

Authors:  Wenting Liu; Kiyosumi Shibata; Yoshihiro Koya; Hiroaki Kajiyama; Takeshi Senga; Mamoru Yamashita; Fumitaka Kikkawa
Journal:  Mol Clin Oncol       Date:  2013-12-12

Review 9.  B7 family checkpoint regulators in immune regulation and disease.

Authors:  Sabrina Ceeraz; Elizabeth C Nowak; Randolph J Noelle
Journal:  Trends Immunol       Date:  2013-08-13       Impact factor: 16.687

10.  B7-H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma.

Authors:  Qiang Dong; Xinlong Ma
Journal:  Biomed Res Int       Date:  2015-04-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.